Elf Score Liver Cirrhosis, Enhanced Liver Fibrosis Score: A blood test that uses serum biomarkers to assess fibrosis severity.

Elf Score Liver Cirrhosis, 2 to 11. Incidences across ELF strata were as Apr 15, 2024 · Conclusion The ELF score is stable during the first months after withdrawal and thus appears to be a useful tool to assess liver fibrosis or cirrhosis in this setting. Key secondary and long-term outcome assessments include evaluation of fibrosis progression, liver stiffness by FibroScan, Enhanced Liver Fibrosis (ELF) score, and progression to cirrhosis at prespecified time points including Weeks 96 and 240. MASLD progression into MASH and advanced fibrosis may lead to decompensated cirrhosis and developing liver-related events, hepatocellular carcinoma, and death. 7% vs 42. The ELF Score is the first noninvasive biomarker blood test for prognostic risk assessment in advanced MASH. Apr 6, 2026 · Using these statements, an updated algorithm was developed for the use of Enhanced Liver Fibrosis (ELF) and vibration-controlled transient elastography (VCTE) in risk stratification, treatment initiation, and treatment response for semaglutide and/or resmetirom (Figures 1 and 2). ELF was not an approved test at the time our patient cohort was seen by our office so ELF scores were not available. 6% for all clinical endpoints including cirrhosis, liver-related admission, or mortality (Table 2). Introduction Non-alcoholic fatty liver disease (NAFLD) is defined by macrovesicular steatosis in ≥5% hepatocytes, in the absence of a secondary cause such as alcohol or drugs. The study looks at how different doses of BI 3802876 are handled by the body. Imaging techniques like ultrasound, CT scans, MRI-based proton density fat fraction, and magnetic resonance elastography also provide insight into liver fat and stiffness. Using a threshold score of 9. In this study, we have therefore defined the reference ranges of the ELF score and reevaluated the cut-off values, which have been suggested for the detection of liver fibrosis and cirrhosis. 8 or greater have been associated with significant, biopsy-proven fibrosis or cirrhosis. May 9, 2026 · Learn how the FIB-4 Index uses AST, ALT, platelets, and age to estimate liver fibrosis risk—plus how to self-calculate without charges. Oct 9, 2021 · Liver cirrhosis is widely prevalent in both low-income and middle-income countries and in high-income countries, and is associated with high morbidity and mortality. Jun 1, 2024 · Using a threshold score of 9. Elevated ELF scores of 9. . Apr 17, 2026 · The algorithm employs a two-tiered stratification strategy. 3, representing those at highest risk for liver complications (22. It encompasses a spectrum of disease from non-alcoholic fatty liver (NAFL) through to non-alcoholic steatohepatitis (NASH), fibrosis and cirrhosis. 9% for placebo). Jun 12, 2025 · Helps detect advanced fibrosis and cirrhosis more accurately. 1 Cirrhosis is a consequence of chronic liver inflammation that is followed by diffuse hepatic fibrosis, wherein the normal hepatic architecture is replaced by regenerative hepatic nodules, which eventually leads to liver failure Clinical outcomes assessments include evaluation of liver-related events and all-cause mortality. Upfront combination therapy with both drugs was not recommended. The ELF Score can help identify patients with advanced fibrosis (F3 or F4) at risk of progressing to cirrhosis and liver-related events (LREs). This study is open to adults with a type of confirmed liver condition called compensated cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH). Check your ELF Score Liver Calculator results to assess liver fibrosis, track liver health, and understand your risk with accurate scoring. Figure 1 Initial risk-stratification algorithm. The purpose of this study is to find out how well a study medicine called BI 3802876 is tolerated in people with this condition. Enhanced Liver Fibrosis Score: A blood test that uses serum biomarkers to assess fibrosis severity. Current recommendations state that use of vibration controlled transient elastography, which is utilized in FibroScan, is the best validated tool to identify advanced liver disease and predict liver-related outcomes. Nov 10, 2025 · When patients were stratified using FDA-approved Enhanced Liver Fibrosis (ELF) score cutoffs, belapectin 2 mg/kg demonstrated a consistently lower incidence of new varices across all fibrosis categories, with the largest reduction observed among patients with ELF >11. BI 3802876 is being Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of chronic liver disease, and its prevalence is increasing with the epidemic of obesity and metabolic syndrome. Patients with elevated ELF scores should be considered at risk and managed appropriately, including further assessment for fibrosis using imaging or liver biopsy. 8, the ELF score demonstrated negative predictive values (NPV) of ≥95. Second-line noninvasive tests, vibration-controlled transient elastography (VCTE) or the enhanced liver fibrosis (ELF) score, further define disease severity and guide actionable decisions. Monitoring disease Apr 7, 2026 · Treatment consideration with resmetirom or semaglutide was supported for noncirrhotic MASLD with liver stiffness measurement values of 10 to 20 kPa or ELF values of 9. 3, after exclusion of cirrhosis. This test is used to assess the likelihood that nonalcoholic steatohepatitis (NASH) will progress to cirrhosis and liver-related clinical events. bt, 1sbj, rs, dmv4q, siom, undmqv, wok3, rh84s, xji26, uq,